文献速递前列腺癌

临床显著前列腺癌高强度聚焦超声局灶治疗后的广泛组织学采样

Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound.
PubMed 文献 · J Urol · 2019-09-06

这项单中心前瞻性研究纳入75例临床显著局限期前列腺癌患者,于2014年4月至2018年4月接受高强度聚焦超声局灶消融,主要终点为6个月经会阴模板饱和穿刺活检检出Gleason评分≥7分的前列腺癌;结果41%的活检者检出临床显著前列腺癌(95%CI 30.3-53.0),无尿垫控尿和足以插入的勃起功能分别保留于63/64例(98.4%)和31/45例(68.9%)。

要点

  • 6个月经会阴模板饱和穿刺活检检出临床显著前列腺癌的比例为41%(95%CI 30.3-53.0)
  • 无尿垫控尿保留于63/64例(98.4%),足以插入的勃起功能保留于31/45例(68.9%)
  • 前列腺特异抗原(OR 1.17,IQR 0.49-2.85,p=0.71)与多参数磁共振成像(敏感度14.3%,IQR 6.7-31.5)预测阳性活检的能力差

核心结论

  • 高强度聚焦超声局灶治疗导致较低的泌尿生殖系统副作用发生率。
  • 对治疗和未治疗前列腺的随访活检仍是充分筛选需要早期挽救治疗男性的唯一方法。

研究设计与样本

  • 单中心前瞻性研究,2014年4月至2018年4月纳入75例接受高强度聚焦超声局灶消融的男性。
  • 术前采用多参数磁共振成像和经会阴模板饱和前列腺穿刺活检定位前列腺癌。
  • 主要终点为6个月随访经会阴模板饱和前列腺穿刺活检检出Gleason评分≥7分的临床显著前列腺癌,泌尿生殖系统副作用为次要关注点。

主要发现

  • 中位年龄67岁(IQR 60-71),中位前列腺特异抗原5.87 ng/ml(IQR 4.65-7.44)。
  • 低危癌症5例(6.7%),中危癌症70例(93.3%)。
  • 6个月接受活检的男性中41%检出临床显著前列腺癌(95%CI 30.3-53.0),中位采样针数44(IQR 36-44)。
  • 前列腺特异抗原(OR 1.17,IQR 0.49-2.85,p=0.71)与多参数磁共振成像(敏感度14.3%,IQR 6.7-31.5)预测阳性活检的能力差。
  • 无尿垫控尿保留于63/64例(98.4%),足以插入的勃起功能保留于31/45例(68.9%)。

临床怎么用

  • 原文结论认为高强度聚焦超声局灶治疗导致较低的泌尿生殖系统副作用发生率。
  • 原文结论认为对治疗和未治疗前列腺的随访活检仍是充分筛选需要早期挽救治疗男性的唯一方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clinically significant, localized prostate cancer is currently treated with whole gland therapy. This approach is effective but associated with genitourinary and rectal side effects. Focal therapy of prostate cancer has been proposed as an alternative. The aim of this study was to determine the oncologic and functional outcomes of focal high intensity focused ultrasound therapy of prostate cancer. MATERIALS AND METHODS: In this single center, prospective study 75 men were treated between April 2014 and April 2018. Multiparametric magnetic resonance imaging and transperineal template saturation prostate biopsy were performed to localize prostate cancer, followed by focal ablation with high intensity focused ultrasound. The study primary end point was the detection of clinically significant prostate cancer, defined as Gleason score 7 or greater, at 6-month followup transperineal template saturation prostate biopsy. Genitourinary side effects were of secondary interest. RESULTS: Median patient age was 67 years (IQR 60-71) and median prostate specific antigen was 5.87 ng/ml (IQR 4.65-7.44). There were 5 low risk (6.7%) and 70 intermediate risk (93.3%) cancers. Clinically significant prostate cancer was detected in 41% of the men (95% CI 30.3-53.0) who underwent biopsy at 6 months and the median number of sampled cores was 44 (IQR 36-44). Prostate specific antigen (OR 1.17, IQR 0.49-2.85, p=0.71) and multiparametric magnetic resonance imaging (14.3% sensitivity, IQR 6.7-31.5) performed poorly to predict positive biopsies. Pad-free continence and erection sufficient for penetration were preserved in 63 of 64 (98.4%) and 31 of 45 patients (68.9%), respectively. CONCLUSIONS: Focal therapy with high intensity focused ultrasound leads to a low rate of genitourinary side effects. Followup biopsy of treated and untreated prostates remains the only modality to adequately select men in need of early salvage treatment.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Mortezavi A, Krauter J, Gu A, et al. Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound. J Urol. 2019. PMID: 31042109. doi:10.1097/JU.0000000000000298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。